The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
Open accessAbstract
The Ki-67 antigen is used to evaluate the proliferative activity of breast cancer (BC); however, Ki-67's role as a prognostic marker in BC is still undefined. In order to better define the prognostic value of Ki-67/MIB-1, we performed a meta-analysis of studies that evaluated the impact of Ki-67/MIB-1 on disease-free survival (DFS) and/or on overall survival (OS) in early BC. Sixty-eight studies were identified and 46 studies including 12 155 patients were evaluable for our meta-analysis; 38 studies were evaluable for the aggregation of results for DFS, and 35 studies for OS. Patients were considered to present positive tumours for the expression of Ki-67/MIB-1 according to the cut-off points defined by the authors. Ki-67/MIB-1 positivity is associated with higher probability of relapse in all patients (HR=1.93 (95% confidence interval (CI): 1.74-2.14); P<0.001), in node-negative patients (HR=2.31 (95% CI: 1.83-2.92); P<0.001) and in node-positive patients (HR=1.59 (95% CI: 1.35-1.87); P<0.001). Furthermore, Ki-67/MIB-1 positivity is associated with worse survival in all patients (HR=1.95 (95% CI: 1.70-2.24; P<0.001)), node-negative patients (HR=2.54 (95% CI: 1.65-3.91); P<0.001) and node-positive patients (HR=2.33 (95% CI: 1.83-2.95); P<0.001). Our meta-analysis suggests that Ki-67/MIB-1 positivity confers a higher risk of relapse and a worse survival in patients with early BC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205 · cited 1×
“The individual HR estimates were combined into an overall HR using the Peto’s method that was first used and published in 1985 (Yusuf et al, 1985).”
MethodGene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Wang, Y., Klijn, J. G., Zhang, Y., Sieuwerts, A. M., Look, M. P., Yang, F., Talantov, D., Timmermans, M., Meijer-van Gelder, M. E., Yu, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17947-1 · Cited by 2,846
Gerdes, J., Schwab, U., Lemke, H., & Stein, H. (1983) · International Journal of Cancer · doi:10.1002/ijc.2910310104 · Cited by 2,788
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,579
Cattoretti, G., Becker, M. H. G., Key, G., Duchrow, M., Schlüuter, C., Galle, J., & Gerdes, J. (1992) · The Journal of Pathology · doi:10.1002/path.1711680404 · Cited by 1,447
Distinctive gene expression patterns in human mammary epithelial cells and breast cancers
Perou, C. M., Jeffrey, S. S., van de Rijn, M., Rees, C. A., Eisen, M. B., Ross, D. T., Pergamenschikov, A., Williams, C. F., Zhu, S. X., Lee, J. C. F., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9212 · Cited by 1,402
Cited by
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Self-citationSystematic reviews: CRD's guidance for undertaking reviews in health care
Tacconelli, E. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70065-7 · Cited by 3,245
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Cheang, M. C. U., Chia, S. K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., Bernard, P. S., Parker, J. S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp082 · Cited by 2,249
Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021) · Cancers · doi:10.3390/cancers13174287 · Cited by 1,960
Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., André, F., Baselga, J., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv221 · Cited by 1,827
Self-citationKi67 in breast cancer: prognostic and predictive potential
Yerushalmi, R., Woods, R., Ravdin, P. M., Hayes, M. M., & Gelmon, K. A. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70262-1 · Cited by 1,207
Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer
Juríková, M., Danihel, Ľ., Polák, Š., & Varga, I. (2016) · Acta Histochemica · doi:10.1016/j.acthis.2016.05.002 · Cited by 608
Inwald, E. C., Klinkhammer-Schalke, M., Hofstädter, F., Zeman, F., Koller, M., Gerstenhauer, M., & Ortmann, O. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2560-8 · Cited by 601
Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature)
Smolarz, B., Nowak, A. Z., & Romanowicz, H. (2022) · Cancers · doi:10.3390/cancers14102569 · Cited by 587
Tumor Heterogeneity in Breast Cancer
Turashvili, G., & Brogi, E. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00227 · Cited by 561
Duffy, M. J., Harbeck, N., Nap, M., Molina, R., Nicolini, A., Senkus, E., & Cardoso, F. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.017 · Cited by 522
Self-citationCurrent and emerging biomarkers in breast cancer: prognosis and prediction
Weigel, M. T., & Dowsett, M. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-10-0136 · Cited by 496
Tuominen, V. J., Ruotoistenmäki, S., Viitanen, A., Jumppanen, M., & Isola, J. (2010) · Breast Cancer Research · doi:10.1186/bcr2615 · Cited by 472
Molecular Subtypes and Local-Regional Control of Breast Cancer
Fragomeni, S. M., Sciallis, A., & Jeruss, J. S. (2018) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.08.005 · Cited by 450
Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives
Ades, F., Zardavas, D., Bozovic-Spasojevic, I., Pugliano, L., Fumagalli, D., de Azambuja, E., Viale, G., Sotiriou, C., & Piccart, M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.1870 · Cited by 435
Self-citationStuart-Harris, R., Caldas, C., Pinder, S. E., & Pharoah, P. (2008) · The Breast · doi:10.1016/j.breast.2008.02.002 · Cited by 431
Breast cancer diagnosis: Imaging techniques and biochemical markers
Jafari, S. H., Saadatpour, Z., Salmaninejad, A., Momeni, F., Mokhtari, M., Nahand, J. S., Rahmati, M., Mirzaei, H., & Kianmehr, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26379 · Cited by 410
Harbeck, N., Rastogi, P., Martin, M., Tolaney, S. M., Shao, Z. M., Fasching, P. A., Huang, C. S., Jaliffe, G. G., Tryakin, A., Goetz, M. P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.015 · Cited by 381
Viale, G., Giobbie-Hurder, A., Regan, M. M., Coates, A. S., Mastropasqua, M. G., Dell'Orto, P., Maiorano, E., MacGrogan, G., Braye, S. G., Öhlschlegel, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.0829 · Cited by 340
Gluz, O., Nitz, U. A., Christgen, M., Kates, R. E., Shak, S., Clemens, M., Kraemer, S., Aktas, B., Kuemmel, S., Reimer, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5383 · Cited by 333
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer
Jones, R. L., Salter, J., A’Hern, R., Nerurkar, A., Parton, M., Reis-Filho, J. S., Smith, I. E., & Dowsett, M. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0081-7 · Cited by 321
Luporsi, E., André, F., Spyratos, F., Martin, P.-M., Jacquemier, J., Penault-Llorca, F., Tubiana-Mathieu, N., Sigal-Zafrani, B., Arnould, L., Gompel, A., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1837-z · Cited by 320
Ki-67 as a prognostic marker according to breast cancer molecular subtype
Nahed, A. S., & Shaimaa, M. Y. (2016) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2016.0066 · Cited by 317
Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer
Davey, M. G., Hynes, S. O., Kerin, M. J., Miller, N., & Lowery, A. J. (2021) · Cancers · doi:10.3390/cancers13174455 · Cited by 298
Robertson, S., Azizpour, H., Smith, K., & Hartman, J. (2018) · Translational Research · doi:10.1016/j.trsl.2017.10.010 · Cited by 295
Hadad, S., Iwamoto, T., Jordan, L., Purdie, C., Bray, S., Baker, L., Jellema, G., Deharo, S., Hardie, D. G., Pusztai, L., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1612-1 · Cited by 293
Petrelli, F., Viale, G., Cabiddu, M., & Barni, S. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3559-0 · Cited by 286
Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists
Johnson, K. S., Conant, E. F., & Soo, M. S. (2021) · Journal of Breast Imaging · doi:10.1093/jbi/wbaa110 · Cited by 280
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
Chen, X., Zhang, M., Gan, H., Wang, H., Lee, J.-H., Fang, D., Kitange, G. J., He, L., Hu, Z., Parney, I. F., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05373-4 · Cited by 273
Laure Giraudet, A., Al Ghulzan, A., Aupérin, A., Leboulleux, S., Chehboun, A., Troalen, F., Dromain, C., Lumbroso, J., Baudin, E., & Schlumberger, M. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0667 · Cited by 272
Molecular classification of breast cancer
Vuong, D., Simpson, P. T., Green, B., Cummings, M. C., & Lakhani, S. R. (2014) · Virchows Archiv · doi:10.1007/s00428-014-1593-7 · Cited by 262
Miyashita, M., Sasano, H., Tamaki, K., Hirakawa, H., Takahashi, Y., Nakagawa, S., Watanabe, G., Tada, H., Suzuki, A., Ohuchi, N., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0632-x · Cited by 253
Mallett, S., Timmer, A., Sauerbrei, W., & Altman, D. G. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605462 · Cited by 122
Why is pancreatic cancer so deadly? The pathologist's view
Hruban, R. H., Gaida, M. M., Thompson, E., Hong, S., Noë, M., Brosens, L. A., Jongepier, M., Offerhaus, G. J. A., & Wood, L. D. (2019) · The Journal of Pathology · doi:10.1002/path.5260 · Cited by 115
NRF2 immunolocalization in human breast cancer patients as a prognostic factor
Onodera, Y., Motohashi, H., Takagi, K., Miki, Y., Shibahara, Y., Watanabe, M., Ishida, T., Hirakawa, H., Sasano, H., Yamamoto, M., et al. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0234 · Cited by 81
The potential utility of geminin as a predictive biomarker in breast cancer.
Sundara Rajan, S., Hanby, A. M., Horgan, K., Thygesen, H. H., & Speirs, V. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2786-5 · Cited by 21
Metadata
- Authors
- de Azambuja, E., Cardoso, F., de Castro, G., Colozza, M., Mano, M. S., Durbecq, V, Sotiriou, C., Larsimont, D., Piccart-Gebhart, M. J., & Paesmans, M.
- Venue
- British Journal of Cancer
- Published
- 2007-04-24
- Volume
- 96
- Issue
- 10
- Pages
- 1504-1513
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2001968322
- Cited by
- 959
- References
- 61
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.